Stocktoria
Jazz Pharmaceuticals plc JAZZ
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2012-01-18
Jazz Pharmaceuticals plc financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B | $2.4B | $2.2B | $1.9B | $1.6B | $1.5B |
| R&D expense | — | — | — | — | — | — | $299.7M | $226.6M | $198.4M | $162.3M |
| SG&A expense | $1.8B | $1.4B | $1.3B | $1.4B | $1.5B | $854.2M | $736.9M | $683.5M | $544.2M | $502.9M |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M | $378.1M | $532.4M | $614.8M | $528.8M | $591.7M |
| Income tax | -$272.4M | -$91.4M | -$119.9M | -$158.6M | $216.1M | $33.5M | -$73.2M | $80.2M | -$47.7M | $135.2M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M | $238.6M | $523.4M | $447.1M | $487.8M | $396.8M |
| EPS (diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 |
| Operating cash flow | $1.4B | $1.4B | $1.1B | $1.3B | $778.5M | $899.6M | $776.4M | $798.9M | $693.1M | $592.4M |
| Free cash flow | $1.3B | $1.4B | $1.1B | $1.2B | $750.9M | $884.6M | $736.3M | $778.5M | — | — |
| Cash & equivalents | $1.4B | $2.4B | $1.5B | $881.5M | $591.4M | $1.1B | $637.3M | $309.6M | $386.0M | $366.0M |
| Inventory | $417.0M | $480.4M | $597.0M | $714.1M | $1.1B | $95.4M | $78.6M | $53.0M | $43.2M | $34.1M |
| Total assets | $11.7B | $12.0B | $11.4B | $10.8B | $12.3B | $6.5B | $5.5B | $5.2B | $5.1B | $4.8B |
| Shareholders' equity | $4.3B | $4.1B | $3.7B | $3.1B | $4.0B | $3.7B | $3.1B | $2.8B | $2.7B | $1.9B |
Growth · year-over-year · Revenue CAGR 12.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +4.9% | +6.1% | +4.8% | +18.3% | +30.9% | +9.3% | +14.3% | +16.8% | +8.8% | +12.3% |
| Net income growth | -163.6% | +35.0% | — | — | -238.2% | -54.4% | +17.1% | -8.4% | +22.9% | +20.4% |
| EPS growth | -167.5% | +41.8% | — | — | -230.8% | -53.6% | +24.5% | -8.3% | +24.2% | +22.6% |
| Free cash flow growth | -4.5% | +27.1% | -14.1% | +65.5% | -15.1% | +20.2% | -5.4% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.